Text Size

Efficacy of Ketorolac 0.4% in Prostaglandin Suppression

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Allergan
ClinicalTrials.gov Identifier:
NCT00791323
First received: November 12, 2008
Last updated: September 21, 2011
Last verified: September 2011
History of Changes
Results First Received: August 17, 2011  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Investigator);   Primary Purpose: Basic Science
Condition: Inflammation
Interventions: Drug: Ketorolac 0.4%
Drug: Lubricating Eye Drop

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Ketorolac 0.4% Ketorolac 0.4%
Soothe® XP Mineral Oil Emollient

Participant Flow:   Overall Study
    Ketorolac 0.4%     Soothe® XP  
STARTED     6     3  
COMPLETED     6     3  
NOT COMPLETED     0     0  



  Baseline Characteristics
  Hide Baseline Characteristics

Reporting Groups
  Description
Ketorolac 0.4% Ketorolac 0.4%
Soothe® XP Mineral Oil Emollient
Total Total of all reporting groups

Baseline Measures
    Ketorolac 0.4%     Soothe® XP     Total  
Number of Participants  
[units: participants]
 		  6     3     9  
Age  
[units: years]
Mean ± Standard Deviation 		  30.2  ± 9.7     33.3  ± 2.5     31.75  ± 6.1  
Gender  
[units: participants]
 		     
Female     5     1     6  
Male     1     2     3  



  Outcome Measures

1.  Primary:   Mean Prostaglandin E2 (PGE2) Aqueous Humor Levels   [ Time Frame: Day 3 ]
  Show Outcome Measure 1


  Serious Adverse Events
  Show Serious Adverse Events


  Other Adverse Events
  Show Other Adverse Events


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Limitations and Caveats
Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.  


Results Point of Contact:  
Name/Title: Vice President Medical Affairs
Organization: Allergan, Inc.
phone: 714-246-4500
e-mail: clinicaltrials@allergan.com


No publications provided


Responsible Party: Allergan
ClinicalTrials.gov Identifier: NCT00791323     History of Changes
Other Study ID Numbers: MA-ACU-08-001
Study First Received: November 12, 2008
Results First Received: August 17, 2011
Last Updated: September 21, 2011
Health Authority: United States: Institutional Review Board